IDEAYA's Darovasertib Combination Hits Primary Endpoint in Uveal Melanoma Trial
Event summary
- IDEAYA's darovasertib combination met primary endpoint in OptimUM-02 trial for metastatic uveal melanoma, with median PFS of 6.9 months vs. 3.1 months.
- NDA filing underway under FDA's RTOR program, completion expected in H2 2026.
- $1.24 billion in cash as of June 30, 2026, with runway guidance into 2030.
- Clinical collaboration with Roche to evaluate IDE892 in combination with RG6505 for pancreatic cancer.
- IDEAYA plans to host R&D Day in Q4 focused on MTAP/CDKN2A, KRAS, and pancreatic cancer.
The big picture
IDEAYA's positive trial results for darovasertib represent a significant milestone in the precision oncology space, particularly for uveal melanoma, a rare and aggressive cancer. The company's strategic collaborations with Roche and Hengrui Pharmaceuticals underscore its focus on expanding its pipeline through targeted combinations. With substantial cash reserves, IDEAYA is well-positioned to navigate the complex regulatory landscape and potentially bring a novel therapy to market.
What we're watching
- Regulatory Approval
- Whether the NDA submission will be accepted under RTOR and the timeline for potential approval.
- Pipeline Progress
- The pace at which IDEAYA can advance its other pipeline candidates, particularly IDE849 and IDE892.
- Commercial Strategy
- How IDEAYA plans to position darovasertib in the market and secure payer coverage for expanded indications.
Related topics